Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Clinical Validation of PITX2 DNA Methylation to Predict Outcome in High-Risk Breast Cancer Patients Treated with Anthracycline-Based Chemotherapy.

Schmitt M, Wilhelm OG, Noske A, Schricker G, Napieralski R, Vetter M, Aubele M, Perkins J, Lauber J, Ulm K, Thomssen C, Martens JWM, Weichert W, Kiechle M.

Breast Care (Basel). 2018 Dec;13(6):425-433. doi: 10.1159/000493016. Epub 2018 Sep 28.

2.

Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer.

Schricker G, Napieralski R, Noske A, Piednoir E, Manner O, Schüren E, Lauber J, Perkins J, Magdolen V, Schmitt M, Ulm K, Weichert W, Kiechle M, Martens JWM, Wilhelm OG.

Sci Rep. 2018 Nov 15;8(1):16861. doi: 10.1038/s41598-018-34919-1.

3.

The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges.

Aubele M, Schmitt M, Napieralski R, Paepke S, Ettl J, Absmaier M, Magdolen V, Martens J, Foekens JA, Wilhelm OG, Kiechle M.

Dis Markers. 2017;2017:4934608. doi: 10.1155/2017/4934608. Epub 2017 Sep 12. Review.

4.

The uPA/uPA receptor system as a target for tumor therapy.

Sperl S, Mueller MM, Wilhelm OG, Schmitt M, Magdolen V, Moroder L.

Drug News Perspect. 2001 Sep;14(7):401-11.

PMID:
12813583
5.

Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.

Schmiedeberg N, Schmitt M, Rölz C, Truffault V, Sukopp M, Bürgle M, Wilhelm OG, Schmalix W, Magdolen V, Kessler H.

J Med Chem. 2002 Nov 7;45(23):4984-94.

PMID:
12408709
6.

Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.

Arroyo De Prada N, Schroeck F, Sinner EK, Muehlenweg B, Twellmeyer J, Sperl S, Wilhelm OG, Schmitt M, Magdolen V.

Eur J Biochem. 2002 Jan;269(1):184-92.

7.

Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).

Magdolen V, Bürgle M, de Prada NA, Schmiedeberg N, Riemer C, Schroeck F, Kellermann J, Degitz K, Wilhelm OG, Schmitt M, Kessler H.

Biol Chem. 2001 Aug;382(8):1197-205.

PMID:
11592401
8.

High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.

Lutz V, Reuning U, Krüger A, Luther T, von Steinburg SP, Graeff H, Schmitt M, Wilhelm OG, Magdolen V.

Biol Chem. 2001 May;382(5):789-98.

PMID:
11517932
9.

Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator.

Magdolen V, Arroyo de Prada N, Sperl S, Muehlenweg B, Luther T, Wilhelm OG, Magdolen U, Graeff H, Reuning U, Schmitt M.

Adv Exp Med Biol. 2000;477:331-41. Review. No abstract available.

PMID:
10849761
10.

(4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.

Sperl S, Jacob U, Arroyo de Prada N, Stürzebecher J, Wilhelm OG, Bode W, Magdolen V, Huber R, Moroder L.

Proc Natl Acad Sci U S A. 2000 May 9;97(10):5113-8.

11.

Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).

Krüger A, Soeltl R, Lutz V, Wilhelm OG, Magdolen V, Rojo EE, Hantzopoulos PA, Graeff H, Gänsbacher B, Schmitt M.

Cancer Gene Ther. 2000 Feb;7(2):292-9.

12.

Epitope mapping of monoclonal antibodies directed to PAI-1 using PAI-1/PAI-2 chimera and PAI-1-derived synthetic peptides.

Muehlenweg B, Guthaus E, de Prada NA, Schmitt M, Schmiedeberg N, Kotzsch M, Creutzburg S, Kramer MD, Kessler H, Wilhelm OG, Magdolen V.

Thromb Res. 2000 Apr 1;98(1):73-81.

PMID:
10706935
13.

Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression.

Wilhelm OG, Wilhelm S, Escott GM, Lutz V, Magdolen V, Schmitt M, Rifkin DB, Wilson EL, Graeff H, Brunner G.

J Cell Physiol. 1999 Aug;180(2):225-35.

PMID:
10395292
15.

The urokinase receptor is a major vitronectin-binding protein on endothelial cells.

Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT.

Exp Cell Res. 1996 May 1;224(2):344-53.

PMID:
8612711
16.

What molecular biology has taught us about fibrinolysis.

Wilhelm OG, Bang NU.

J Lab Clin Med. 1992 Feb;119(2):111-5. Review. No abstract available.

PMID:
1740623
17.

Disulfide pairing of the recombinant kringle-2 domain of tissue plasminogen activator produced in Escherichia coli.

Vlahos CJ, Wilhelm OG, Hassell T, Jaskunas SR, Bang NU.

J Biol Chem. 1991 Jun 5;266(16):10070-2.

18.

Functional properties of the recombinant kringle-2 domain of tissue plasminogen activator produced in Escherichia coli.

Wilhelm OG, Jaskunas SR, Vlahos CJ, Bang NU.

J Biol Chem. 1990 Aug 25;265(24):14606-11.

19.

After coronary thrombolysis and reperfusion, what next?

Bang NU, Wilhelm OG, Clayman MD.

J Am Coll Cardiol. 1989 Oct;14(4):837-49. Review.

20.

Thrombolytic therapy in acute myocardial infarction.

Bang NU, Wilhelm OG, Clayman MD.

Annu Rev Pharmacol Toxicol. 1989;29:323-41. Review. No abstract available.

PMID:
2658773

Supplemental Content

Loading ...
Support Center